TGFB1 and cancer: Thus, neutralizing Itgβ8 is sufficient to impair TGF-β signaling in CD8pos T lymphocytes infiltrating human tumors and boost their cytotoxic functions, opening the path toward clinical applications based on Itgβ8 targeting in cancer.